Indaptus Therapeutics, Inc. to Post Q1 2024 Earnings of ($0.57) Per Share, HC Wainwright Forecasts (NASDAQ:INDP)

Indaptus Therapeutics, Inc. (NASDAQ:INDP) – Equities research analysts at HC Wainwright dropped their Q1 2024 earnings per share estimates for shares of Indaptus Therapeutics in a research note issued on Monday, April 15th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.57) per share for the quarter, down from their prior forecast of ($0.44). HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Indaptus Therapeutics’ current full-year earnings is ($1.83) per share. HC Wainwright also issued estimates for Indaptus Therapeutics’ Q2 2024 earnings at ($0.60) EPS, Q4 2024 earnings at ($0.34) EPS and FY2024 earnings at ($1.83) EPS.

Indaptus Therapeutics Trading Down 5.3 %

Shares of INDP opened at $2.52 on Wednesday. The company has a market capitalization of $21.52 million, a PE ratio of -1.37 and a beta of 1.28. The stock’s 50-day moving average price is $2.15 and its two-hundred day moving average price is $2.11. Indaptus Therapeutics has a 12 month low of $1.56 and a 12 month high of $4.08.

Indaptus Therapeutics (NASDAQ:INDP) last announced its earnings results on Wednesday, March 13th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.07.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in Indaptus Therapeutics by 2.2% during the 4th quarter. Vanguard Group Inc. now owns 256,265 shares of the company’s stock worth $451,000 after purchasing an additional 5,517 shares in the last quarter. Northern Trust Corp purchased a new stake in shares of Indaptus Therapeutics during the first quarter worth $41,000. Citadel Advisors LLC purchased a new stake in shares of Indaptus Therapeutics during the fourth quarter worth $29,000. State Street Corp purchased a new stake in shares of Indaptus Therapeutics during the first quarter worth $78,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of Indaptus Therapeutics in the second quarter worth $51,000. 7.06% of the stock is owned by institutional investors and hedge funds.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.